Affinage

CFH

Complement factor H · UniProt P08603

Length
1231 aa
Mass
139.1 kDa
Annotated
2026-06-09
100 papers in source corpus 14 papers cited in narrative 14 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CFH encodes complement factor H (FH), the major soluble and cell-surface regulator of the alternative complement pathway, acting through C3b binding to restrain complement activation on host surfaces (PMID:19297022, PMID:16621965). Loss-of-function arises through multiple routes that converge on impaired regulation: missense mutations that reduce protein expression or abolish C3b binding, C-terminal variants such as R1210C that abrogate surface-recognition ligand binding, autoantibodies that block the C-terminal recognition function (notably in patients carrying CFHR1/CFHR3 deletions, defining DEAP-HUS), and CFH::CFHR1 hybrid genes generated by structural rearrangement (PMID:16621965, PMID:22019782, PMID:20157737, PMID:19190803, PMID:36793547). These defects cause uncontrolled complement activation underlying atypical hemolytic uremic syndrome, membranoproliferative/C3 glomerulopathy, and age-related macular degeneration, with phenotype determined by whether plasma-bound or surface-bound FH function is impaired (PMID:19297022, PMID:16621965, PMID:22019782); coding variation in CFH directly modulates AMD susceptibility, with R1210C strongly raising risk and N1050Y protective (PMID:28011711). In the retina, FH is synthesized locally by the retinal pigmented epithelium, where it accumulates in drusen and acts as the principal local inhibitor of the alternative pathway (PMID:15870199). RPE-derived FH also serves an autocrine homeostatic role: its loss elevates inflammatory mediators (IL-6, IL-8, GM-CSF) and remodels complement protein levels through NF-κB signaling (PMID:34445430), and the Y402H at-risk variant is linked to increased C5a, IL-18, and TNF-α and inflammasome-associated NF-κB activation in RPE (PMID:26746578). CFH expression is post-transcriptionally repressed by NF-κB-induced miR-125b and miR-146a in neuroinflammatory contexts (PMID:22302353). A distinct role in maintaining cancer stem-cell properties has been described in liver cancer cells, mediated through CFH-dependent LSF-1 expression (PMID:26723877).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2005 Medium

    Established that CFH is not only a plasma protein but is synthesized locally in the eye and accumulates in disease deposits, defining a tissue-resident role for complement regulation in the retina.

    Evidence Immunolocalization of FH in drusen and RPE synthesis with parallel AMD genetic association

    PMID:15870199

    Open questions at the time
    • Does not establish the molecular regulatory mechanism of local FH
    • Causal direction between drusen FH accumulation and AMD not resolved
  2. 2006 High

    Showed that aHUS-associated CFH mutations cause disease either by lowering protein levels or by abolishing C3b binding, directly linking loss of FH-mediated C3b inactivation to complement dysregulation.

    Evidence Genetic screening of 156 aHUS patients with C3b-binding and expression functional assays

    PMID:16621965

    Open questions at the time
    • Does not separate surface-bound from fluid-phase regulatory defects
    • Does not address downstream tissue injury mechanism
  3. 2009 Medium

    Distinguished plasma-bound from surface-bound FH function, explaining how different CFH mutations produce distinct diseases (MPGN, aHUS, AMD), and identified acquired autoantibody-mediated FH inhibition as a parallel disease mechanism.

    Evidence Mutational/functional correlation review plus autoantibody detection with CFHR1/CFHR3 genotyping and complement assays

    PMID:19190803 PMID:19297022

    Open questions at the time
    • Genotype-to-tissue-specificity link remains correlative
    • Mechanism by which CFHR1/CFHR3 deletion predisposes to autoantibodies not resolved
  4. 2010 Medium

    Localized the functional autoantibody epitope to the FH C-terminus, showing autoantibodies phenocopy genetic C-terminal mutations by blocking surface recognition, and defined the DEAP-HUS subgroup.

    Evidence Epitope characterization of anti-FH IgG with CFHR1/CFHR3 deletion correlation

    PMID:20157737

    Open questions at the time
    • Does not establish why autoantibodies arise in CFHR-deficient patients
    • Single-review consolidation rather than primary structural mapping
  5. 2011 High

    Demonstrated that a single C-terminal variant (R1210C) abrogating ligand binding drives risk across two distinct diseases, unifying aHUS and AMD around loss of the surface-recognition function of FH.

    Evidence Sequencing and genotyping in 2,423 AMD cases and 1,122 controls with prior biochemical characterization

    PMID:22019782

    Open questions at the time
    • Does not explain divergent organ targeting of the same variant
    • Mechanism of penetrance modulation unknown
  6. 2012 Medium

    Identified a post-transcriptional control layer for CFH, showing NF-κB-induced miR-125b and miR-146a repress CFH mRNA in inflammatory conditions.

    Evidence miRNA overexpression in primary human neuronal-glial cells with qPCR of CFH

    PMID:22302353

    Open questions at the time
    • Direct miRNA-CFH 3'UTR binding not demonstrated here
    • Protein-level and functional consequences not quantified
  7. 2015 Medium

    Revealed a non-complement role for CFH in sustaining liver cancer stem-cell properties via LSF-1-driven stemness transcription, expanding FH function beyond complement regulation.

    Evidence siRNA knockdown/overexpression, tumorsphere assays, xenografts, and LSF-1 expression analysis in liver cancer lines

    PMID:26723877

    Open questions at the time
    • Mechanism linking CFH to LSF-1 not defined
    • Independence from complement activity not established
  8. 2016 Medium

    Connected the Y402H risk variant to inflammasome and cytokine signaling, showing elevated C5a/IL-18/TNF-α in choroid and C5a-driven NF-κB activation in RPE.

    Evidence Genotyped donor-eye protein quantification with polarized ARPE19 stimulation and NF-κB reporter assays

    PMID:26746578

    Open questions at the time
    • Causal chain from Y402H to elevated C5a not directly demonstrated
    • Single-lab cell-model findings
  9. 2017 Medium

    Quantified directionality of CFH coding variation in AMD, confirming N1050Y protection and R1210C high risk through altered protein function.

    Evidence Exome-chip meta-analysis in 4,332 cases and 25,268 controls with functional annotation

    PMID:28011711

    Open questions at the time
    • Functional consequences inferred from prior biochemistry, not measured here
    • Tissue-level mechanism not addressed
  10. 2021 Medium

    Refined the AMD risk model by showing common CFH variants associate with elevated FHR protein levels rather than altered FH levels, implicating the FH/FHR balance.

    Evidence ELISA quantification of FH/FHR in 202 controls and 216 AMD patients with genotype association and choroid/drusen immunolocalization

    PMID:34260947

    Open questions at the time
    • Does not establish the regulatory mechanism by which FHR proteins promote risk
    • Single study design
  11. 2021 Medium

    Defined an autocrine homeostatic function for RPE-derived FH, showing its loss raises inflammatory mediators and remodels complement protein expression via NF-κB.

    Evidence CFH siRNA knockdown in hTERT-RPE1 cells with cytokine/complement quantification and NF-κB inhibition

    PMID:34445430

    Open questions at the time
    • Intracellular versus secreted FH contributions not separated
    • Single-lab cell-line model
  12. 2023 Medium

    Characterized CFH-CFHR structural rearrangements (including CFH::CFHR1 hybrids) as drivers of complement-mediated aHUS with poor prognosis, with anti-C5 (eculizumab) inducing remission.

    Evidence MLPA and long-read SMRT sequencing in 258 primary and 92 secondary aHUS patients with clinical outcome analysis

    PMID:36793547

    Open questions at the time
    • Precise functional defect of hybrid protein inferred from known biology
    • Mechanism of breakpoint formation not resolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the FH/FHR protein balance, local RPE FH synthesis, and the same C-terminal recognition defect together determine organ-specific disease (kidney versus retina) remains unresolved.
  • No unified model of tissue-specific phenotype from shared molecular defects
  • Direct structural mechanism of FHR competition with FH not established
  • Functional link between non-complement (cancer stemness) and complement roles unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 3 GO:0140313 molecular sequestering activity 2
Localization
GO:0005576 extracellular region 2 GO:0005886 plasma membrane 2
Pathway
R-HSA-1643685 Disease 3 R-HSA-168256 Immune System 3
Partners
C3CFHR1CFHR3CFI

Evidence

Reading pass · 14 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2005 Factor H (CFH) protein accumulates within drusen and is synthesized by the retinal pigmented epithelium, establishing a local role for CFH as the major inhibitor of the alternative complement pathway in the retina. Immunohistochemistry/immunolocalization combined with genetic association analysis in AMD cases and controls Proceedings of the National Academy of Sciences of the United States of America Medium 15870199
2009 CFH functions as a complement inhibitor present both as a soluble plasma protein and cell surface-attached form; mutations in CFH differentially affect plasma-bound versus surface-bound CFH function, producing distinct phenotypic outcomes (membranoproliferative glomerulonephritis, atypical HUS, or AMD) depending on which function is impaired. Mutational analysis correlated with functional assays (C3b binding, complement regulation) and clinical phenotyping Molecular immunology Medium 19297022
2006 CFH mutations in atypical HUS patients result in either reduced protein expression or impaired C3b binding capability, demonstrating that loss of CFH-mediated C3b inactivation drives complement dysregulation and disease. Genetic screening of 156 aHUS patients combined with functional assays for C3b binding and protein expression levels Blood High 16621965
2011 A rare CFH missense variant R1210C abrogates C-terminal ligand binding of CFH, demonstrating that loss of CFH's C-terminal surface-recognition function drives both atypical HUS and AMD risk. High-throughput sequencing to identify variant, genotyping in 2,423 AMD cases and 1,122 controls, prior biochemical characterization of C-terminal ligand binding abrogation Nature genetics High 22019782
2010 Autoantibodies targeting CFH in atypical HUS patients block CFH surface recognition at the C-terminus, mimicking the functional effect of genetic CFH mutations and impairing complement regulation on host cell surfaces; this occurs almost exclusively in patients with CFHR1/CFHR3 deletion (DEAP-HUS). Immunological characterization of IgG autoantibodies to Factor H, correlation with CFHR1/CFHR3 deletion genotyping and complement functional assays Pediatric nephrology (Berlin, Germany) Medium 20157737
2009 IgG autoantibodies to Factor H in aHUS patients impair complement regulation by binding CFH, representing an acquired mechanism of complement dysregulation that defines the DEAP-HUS subgroup with CFHR1/CFHR3 protein deficiency. Autoantibody detection, CFHR1/CFHR3 deletion genotyping, complement pathway functional assessment Thrombosis and haemostasis Medium 19190803
2012 miR-125b and miR-146a, upregulated by NF-κB activation in response to IL-1β and Aβ42 in human neuronal-glial cells, target CFH mRNA and cause significant decreases in CFH expression, establishing a post-transcriptional regulatory mechanism for CFH in neuroinflammation. miRNA overexpression in primary human neuronal-glial cell cultures, qPCR measurement of CFH expression, NF-κB pathway analysis Molecular neurobiology Medium 22302353
2021 Loss of endogenous CFH in human RPE cells leads to increased inflammatory mediators (IL-6, IL-8, GM-CSF) and altered complement protein levels (C3 and CFB upregulation, C5 downregulation), with NF-κB identified as the major pathway mediating these effects, establishing an autocrine role for RPE-derived CFH in maintaining inflammatory and complement homeostasis. CFH siRNA knockdown in hTERT-RPE1 cells, cytokine/complement protein quantification, NF-κB pathway inhibition International journal of molecular sciences Medium 34445430
2015 CFH is required to maintain stemness in liver cancer cells; knockdown of CFH abrogates tumorsphere formation and induces differentiation, while overexpression stimulates stemness factor expression and in vivo cell growth, mechanistically through CFH-dependent LSF-1 expression which drives stemness factor transcription. siRNA knockdown and overexpression in liver cancer cell lines, tumorsphere assay, in vivo xenograft, LSF-1 expression analysis Cancer letters Medium 26723877
2016 The CFH Y402H at-risk polymorphism is associated with higher C5a, IL-18, and TNF-α levels in Bruch's membrane/choroid; C5a promotes NF-κB activation and IL-18 upregulation in polarized RPE cells, establishing a mechanistic link between the Y402H variant, complement activation, and inflammasome pathway regulation in AMD pathology. Post-mortem donor eye genotyping with protein quantification, polarized ARPE19 cell stimulation with C5a/TNF-α, NF-κB reporter assay, gene expression analysis The British journal of ophthalmology Medium 26746578
2019 Molecular docking and experimental alanine scanning confirmed that the human anti-CFH antibody Ab42 interacts with CFH polypeptide through hydrogen bonds involving CDR residues (Tyr315, Ser100, Gly33, Tyr53) contacting CFH residues Pro441, Ile442, Asp443, Asn444, Ile447, and Thr448, defining the structural epitope of this interaction. Molecular docking, molecular dynamics simulation, free energy calculation, experimental alanine scanning mutagenesis International journal of molecular sciences Medium 31130605
2021 Common AMD-associated CFH variants (e.g., FH p.Tyr402His/Y402H) strongly associate with elevated plasma FHR-1, FHR-2, FHR-3, and FHR-4A concentrations but not with FH (CFH protein) concentrations, suggesting that CFH genetic variants modulate AMD risk predominantly through effects on FHR protein levels rather than FH protein levels. ELISA quantification of FH and FHR proteins in 202 controls and 216 AMD patients, genotype-protein association analysis, immunolocalization of FHR-2 and FHR-5 in choroid and drusen American journal of human genetics Medium 34260947
2017 A missense variant N1050Y in CFH is protective against AMD (OR=0.76), and the rare R1210C variant confers high AMD risk (OR=18.82), with both variants having known functional consequences on CFH ligand binding, confirming that coding variation in CFH directly modulates AMD susceptibility through altered protein function. Exome chip genotyping meta-analysis in 4,332 cases and 25,268 controls; functional annotation of variants Human molecular genetics Medium 28011711
2023 Structural variants involving CFH-CFHR rearrangements in aHUS patients include CFH::CFHR1 hybrid genes that produce dysfunctional CFH protein, and are associated with poor prognosis; eculizumab (anti-C5) treatment induced remission in affected acute episodes, confirming that CFH structural variants drive complement-mediated aHUS through loss of complement regulation. MLPA copy number variation analysis, long-read SMRT sequencing for breakpoint characterization in 258 primary aHUS and 92 secondary aHUS patients, clinical outcome analysis Frontiers in immunology Medium 36793547

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2005 A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America 1648 15870199
1998 The OxyS regulatory RNA represses rpoS translation and binds the Hfq (HF-I) protein. The EMBO journal 590 9774349
2006 Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 555 16621965
2012 STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nature reviews. Nephrology 291 22986360
2022 Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC. Heart failure 270 36202739
2011 A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nature genetics 270 22019782
2002 Caenorhabditis elegans HUS-1 is a DNA damage checkpoint protein required for genome stability and EGL-1-mediated apoptosis. Current biology : CB 226 12445383
2017 HUS and atypical HUS. Blood 210 28416508
2006 Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: Characterization, ethnic distribution and evolutionary implications. Annals of medicine 193 28950782
2019 B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. Journal of the American College of Cardiology 174 30846338
2012 Renal and neurological involvement in typical Shiga toxin-associated HUS. Nature reviews. Nephrology 163 22986362
2000 Hfq (HF1) stimulates ompA mRNA decay by interfering with ribosome binding. Genes & development 151 10809669
2020 Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European heart journal 145 32221582
2006 CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age-related macular degeneration. Human heredity 142 16816528
2012 Regulation of complement factor H (CFH) by multiple miRNAs in Alzheimer's disease (AD) brain. Molecular neurobiology 133 22302353
2006 Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Annals of medicine 133 17438673
2008 CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 132 18423869
2011 Alternative complement pathway assessment in patients with atypical HUS. Journal of immunological methods 122 21215749
2022 Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Circulation 120 35971840
2016 Geographic variations in the PARADIGM-HF heart failure trial. European heart journal 120 27354044
2020 Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC. Heart failure 116 33004114
2010 Genetics and complement in atypical HUS. Pediatric nephrology (Berlin, Germany) 115 20526633
2008 HF diets increase hypothalamic PTP1B and induce leptin resistance through both leptin-dependent and -independent mechanisms. American journal of physiology. Endocrinology and metabolism 115 19017730
1996 An HF-1a/HF-1b/MEF-2 combinatorial element confers cardiac ventricular specificity and established an anterior-posterior gradient of expression. Development (Cambridge, England) 108 8674419
2023 Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. European heart journal 98 37210743
2013 CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology 92 23972322
2007 Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice. Molecular therapy : the journal of the American Society of Gene Therapy 86 17565352
1993 HF1 and HF2: novel bacteriophages of halophilic archaea. Virology 83 8249290
2009 The spectrum of phenotypes caused by variants in the CFH gene. Molecular immunology 81 19297022
2013 Genetic influences on plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular degeneration. Human molecular genetics 76 23873044
2006 Analysis of CFH, TLR4, and APOE polymorphism in India suggests the Tyr402His variant of CFH to be a global marker for age-related macular degeneration. Investigative ophthalmology & visual science 75 16936080
2008 Gene-environment interaction in progression of AMD: the CFH gene, smoking and exposure to chronic infection. Human molecular genetics 74 18203751
2021 Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC. Heart failure 72 33549556
2023 Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION HF. JACC. Heart failure 70 37354145
2018 Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). Pediatric nephrology (Berlin, Germany) 67 30382336
2020 Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study. Revista espanola de cardiologia (English ed.) 65 33380382
2009 Autoantibodies in haemolytic uraemic syndrome (HUS). Thrombosis and haemostasis 64 19190803
2010 DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatric nephrology (Berlin, Germany) 63 20157737
2010 C-reactive protein and CFH, ARMS2/HTRA1 gene variants are independently associated with risk of macular degeneration. Ophthalmology 63 20346514
2006 Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy. Molecular therapy : the journal of the American Society of Gene Therapy 61 16324888
2019 Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure. Circulation research 59 31318648
2015 CFH Variants Affect Structural and Functional Brain Changes and Genetic Risk of Alzheimer's Disease. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 55 26243271
2009 Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney international. Supplement 55 19180140
2021 Common haplotypes at the CFH locus and low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations and age-related macular degeneration. American journal of human genetics 54 34260947
2015 Complement proteins C7 and CFH control the stemness of liver cancer cells via LSF-1. Cancer letters 54 26723877
2020 Serum potassium in the PARADIGM-HF trial. European journal of heart failure 52 32809261
2019 MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT. JACC. Heart failure 48 31779922
2015 MicroRNAs (miRNAs) in the control of HF development and cycling: the next frontiers in hair research. Experimental dermatology 46 26121602
2004 Haloviruses HF1 and HF2: evidence for a recent and large recombination event. Journal of bacteriology 46 15090523
2004 Mutations in CD46, a complement regulatory protein, predispose to atypical HUS. Trends in molecular medicine 41 15121049
2018 Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). Pediatric nephrology (Berlin, Germany) 40 29372302
2016 CFH Y402H polymorphism and the complement activation product C5a: effects on NF-κB activation and inflammasome gene regulation. The British journal of ophthalmology 40 26746578
2013 DGKE and atypical HUS. Nature genetics 40 23619787
2020 Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. JACC. Heart failure 38 33189633
2018 Circular RNA Complement Factor H (CFH) Promotes Glioma Progression by Sponging miR-149 and Regulating AKT1. Medical science monitor : international medical journal of experimental and clinical research 38 30111766
2021 CFH Loss in Human RPE Cells Leads to Inflammation and Complement System Dysregulation via the NF-κB Pathway. International journal of molecular sciences 36 34445430
2010 CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. Journal of ocular biology, diseases, and informatics 35 21811649
2021 Protective chromosome 1q32 haplotypes mitigate risk for age-related macular degeneration associated with the CFH-CFHR5 and ARMS2/HTRA1 loci. Human genomics 34 34563268
2023 Hafnium (Hf)-Chelating Porphyrin-Decorated Gold Nanosensitizers for Enhanced Radio-Radiodynamic Therapy of Colon Carcinoma. ACS nano 33 38063344
2017 The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. American heart journal 33 28577679
2013 Association of CFH and CFB gene polymorphisms with retinopathy in type 2 diabetic patients. Mediators of inflammation 33 23864767
2013 Successful treatment of DEAP-HUS with eculizumab. Pediatric nephrology (Berlin, Germany) 33 24249282
2024 Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF. Journal of the American College of Cardiology 32 39520455
2023 Activation of MAP2K signaling by genetic engineering or HF-rTMS promotes corticospinal axon sprouting and functional regeneration. Science translational medicine 32 36599003
2021 Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. Journal of cardiac failure 32 34793971
2019 Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide. International journal of molecular sciences 32 31130605
2017 Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology 32 29288229
2017 Thrombotic Microangiopathies (TTP, HUS, HELLP). Hematology/oncology clinics of North America 31 29078925
2009 Pathological aspects of membranoproliferative glomerulonephritis (MPGN) and haemolytic uraemic syndrome (HUS) / thrombocytic thrombopenic purpura (TTP). Thrombosis and haemostasis 31 19190808
2022 Progression of Age-Related Macular Degeneration Among Individuals Homozygous for Risk Alleles on Chromosome 1 (CFH-CFHR5) or Chromosome 10 (ARMS2/HTRA1) or Both. JAMA ophthalmology 29 35113155
2014 Thrombotic microangiopathies (TTP, HUS, HELLP). Emergency medicine clinics of North America 28 25060255
2021 CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Frontiers in genetics 26 34211499
2021 Dual-Selective Catalysis in Dephosphorylation Tuned by Hf6-Containing Metal-Organic Frameworks Mimicking Phosphatase. ACS central science 24 34079899
2014 FPR1 interacts with CFH, HTRA1 and smoking in exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Eye (London, England) 24 25277308
2013 HUS and TTP in Children. Pediatric clinics of North America 24 24237985
2009 Severe atypical HUS caused by CFH S1191L--case presentation and review of treatment options. Pediatric nephrology (Berlin, Germany) 24 19856002
2007 Phylogenetic analysis of the genus Petunia (Solanaceae) based on the sequence of the Hf1 gene. Journal of plant research 24 17353990
2023 Unconventional Polarization-Switching Mechanism in (Hf, Zr)O_{2} Ferroelectrics and Its Implications. Physical review letters 23 38101373
2022 Effects of HF-rTMS on microglial polarization and white matter integrity in rats with poststroke cognitive impairment. Behavioural brain research 23 36455674
2017 Influence of CFH gene on symptom severity of schizophrenia. Neuropsychiatric disease and treatment 23 28293111
2015 Association of Smoking and CFH and ARMS2 Risk Variants With Younger Age at Onset of Neovascular Age-Related Macular Degeneration. JAMA ophthalmology 23 25695752
2024 Point-of-care AI-enhanced novice echocardiography for screening heart failure (PANES-HF). Scientific reports 22 38866831
2017 A novel, multiplexed targeted mass spectrometry assay for quantification of complement factor H (CFH) variants and CFH-related proteins 1-5 in human plasma. Proteomics 22 27647805
2013 hF-measure: A new measurement for evaluating clusters in protein-protein interaction networks. Proteomics 22 23193073
2013 Complement factor H gene (CFH) polymorphisms C-257T, G257A and haplotypes are associated with protection against severe dengue phenotype, possible related with high CFH expression. Human immunology 20 23747994
2023 CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome. Frontiers in immunology 19 36793547
2021 Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. Circulation. Heart failure 19 33706551
2016 HF-Free Boc Synthesis of Peptide Thioesters for Ligation and Cyclization. Angewandte Chemie (International ed. in English) 19 27654901
1999 Integrated genetic and physical map of the 1q31-->q32.1 region, encompassing the RP12 locus, the F13B and HF1 genes, and the EEF1AL11 and RPL30 pseudogenes. Cytogenetics and cell genetics 19 10343093
2022 PBX1-SIRT1 Positive Feedback Loop Attenuates ROS-Mediated HF-MSC Senescence and Apoptosis. Stem cell reviews and reports 18 35962175
2008 TTP-HUS associated with sunitinib. Cancer research and treatment 18 19688133
2016 Protective coding variants in CFH and PELI3 and a variant near CTRB1 are associated with age-related macular degeneration†. Human molecular genetics 17 28011711
2015 CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). Pediatric nephrology (Berlin, Germany) 17 26399238
2024 SpCas9-HF1 enhances accuracy of cell cycle-dependent genome editing by increasing HDR efficiency, and by reducing off-target effects and indel rates. Molecular therapy. Nucleic acids 16 38328481
2024 Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial. JACC. Heart failure 16 39111953
2021 LIPCAR Is Increased in Chronic Symptomatic HF Patients. A Sub-Study of the GISSI-HF Trial. Clinical chemistry 16 34751777
2020 Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. JACC. Heart failure 16 32919915
2016 Critical Questions about PARADIGM-HF and the Future. Acta Cardiologica Sinica 16 27471351
2014 CFH haplotypes and ARMS2, C2, C3, and CFB alleles show association with susceptibility to age-related macular degeneration in Mexicans. Molecular vision 16 24453474
2020 Pathogenic functions and diagnostic utility of cytokines/chemokines in EHEC-HUS. Pediatrics international : official journal of the Japan Pediatric Society 15 31742829

Missed literature

Know a paper Affinage missed for CFH? Flag it for the maintainers and the community.

No submissions yet.